東富龍(300171.SZ):子公司擬在金山工業區投建生物製藥系統裝備產業化項目 預計投資額5億元
格隆匯 12 月 23日丨東富龍(300171.SZ)公佈,公司於2020年12月22日召開第五屆董事會第六次(臨時)會議、第五屆監事會第六次(臨時)會議,審議通過《關於公司子公司擬簽訂投資項目服務協議的議案》,公司全資子公司上海東富龍製藥設備製造有限公司(“東富龍製造”)與上海新金山工業投資發展有限公司(“金山投資”)擬簽署《投資項目服務協議書》,計劃於上海市金山區金山工業區投資建設生物製藥系統裝備產業化項目,預計投資額為人民幣5億元。
東富龍製造在金山區金山工業區計劃投資建設生物製藥系統裝備產業化項目,總投資5億元人民幣。第一期投資3.5億元,計劃3年投產,5年實現達產,達產年產值在5億元人民幣以上,整體税收在5000萬元人民幣以上,項目投資強度不低於800萬元人民幣/畝。項目建設用地土地出讓價格為80萬元人民幣/畝(具體以實際掛牌價為準),建設用地土地指標費為30萬元人民幣/畝,雙方各自承擔50%,即15萬元人民幣/畝。
自國家出台《“十三五”生物產業發展規劃內容》、《中國製造2025》等政策,生物醫藥一直作為重點發展領域及重點支持產業,東富龍作為生物製藥企業的裝備製造商和服務商,力爭為生物製藥企業提供更多優質的產品及服務。此次東富龍製造與金山投資擬簽訂投資項目服務協議,計劃投資建設生物製藥系統裝備產業化項目,有利於公司擴大生物裝備製造產能,進一步增強公司生物工程整體解決方案能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.